© 2020 Marker Therapeutics, Inc.
A Florida-based biotechnology company has received fast-track designation from the Food and Drug Administration to develop immunotherapy treatments for ovarian and breast cancers.
Hear from Randal H. Henderson, MD,Professor,Department of Radiation Oncology and Associate Medical Director at the UF Health Proton Therapy Institute, and enjoy a panel discussion led by Glynn Wilson, PhD, Chairman & CEO of TapImmune, Inc.
Robin McCallum manages all aspects of CMC Operations for TapImmune’s cancer vaccine programs.